Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

HER2 Testing in Breast Carcinoma Very Low Concordance Rate Between Reference and Local Laboratories in Brazil

HER2 Testing in Breast Carcinoma Very Low Concordance Rate Between Reference and Local... RESEARCH ARTICLE HER2 Testing in Breast Carcinoma Very Low Concordance Rate Between Reference and Local Laboratories in Brazil Sheila Cristina Lordelo Wludarski, MD,*w Lisandro Ferreira Lopes, MD, PhD,* Ta´cio R. Berto e Silva, MD,* Filomena M. Carvalho, MD, PhD,w Lawrence M. Weiss, MD,z and Carlos E. Bacchi, MD, PhD*w ERBB2. This receptor has tyrosine kinase activity and is Abstract: Breast cancer accounts for approximately one involved in cellular signaling that regulates cell growth 3,4 quarter of all cancers in females. HER2 gene amplification or and development. HER2 gene amplification or HER2 HER2 protein overexpression, detected in about 20% of breast protein overexpression, detected in approximately 20% carcinomas, predicts a more aggressive clinical course and of breast carcinomas, predicts a more aggressive clinical determines eligibility for targeted therapy with trastuzumab. course with a worse response to hormonal therapy and HER2 testing has become an essential part of the clinical determines eligibility for targeted therapy with the anti- evaluation of all breast carcinoma patients, and accurate HER2 HER2 monoclonal antibody called trastuzumab (Her- results are critical in identifying patients who may be benefited ceptin, Genentech Inc, South San Francisco, CA). For from targeted therapy. This study investigated the concordance these reasons, http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Applied Immunohistochemistry & Molecular Morphology Wolters Kluwer Health

HER2 Testing in Breast Carcinoma Very Low Concordance Rate Between Reference and Local Laboratories in Brazil

Loading next page...
 
/lp/wolters-kluwer-health/her2-testing-in-breast-carcinoma-very-low-concordance-rate-between-lraDdSiBWk

References (55)

Copyright
Copyright #x00A9; 2011 by Lippincott Williams & Wilkins
ISSN
1541-2016
DOI
10.1097/PAI.0b013e3181f0b044
pmid
20930616
Publisher site
See Article on Publisher Site

Abstract

RESEARCH ARTICLE HER2 Testing in Breast Carcinoma Very Low Concordance Rate Between Reference and Local Laboratories in Brazil Sheila Cristina Lordelo Wludarski, MD,*w Lisandro Ferreira Lopes, MD, PhD,* Ta´cio R. Berto e Silva, MD,* Filomena M. Carvalho, MD, PhD,w Lawrence M. Weiss, MD,z and Carlos E. Bacchi, MD, PhD*w ERBB2. This receptor has tyrosine kinase activity and is Abstract: Breast cancer accounts for approximately one involved in cellular signaling that regulates cell growth 3,4 quarter of all cancers in females. HER2 gene amplification or and development. HER2 gene amplification or HER2 HER2 protein overexpression, detected in about 20% of breast protein overexpression, detected in approximately 20% carcinomas, predicts a more aggressive clinical course and of breast carcinomas, predicts a more aggressive clinical determines eligibility for targeted therapy with trastuzumab. course with a worse response to hormonal therapy and HER2 testing has become an essential part of the clinical determines eligibility for targeted therapy with the anti- evaluation of all breast carcinoma patients, and accurate HER2 HER2 monoclonal antibody called trastuzumab (Her- results are critical in identifying patients who may be benefited ceptin, Genentech Inc, South San Francisco, CA). For from targeted therapy. This study investigated the concordance these reasons,

Journal

Applied Immunohistochemistry & Molecular MorphologyWolters Kluwer Health

Published: Mar 1, 2011

There are no references for this article.